Vanda Wins Appeal Case on Fanapt®
2018-04-13 · Vanda Pharmaceuticals · original vandapharma.com ↗
WASHINGTON , April 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that West Ward Pharmaceuticals , a subsidiary of Hikma Pharmaceuticals , infringed Vanda's U.S. Patent number 8,586,610 (the '610 Patent) for Fanapt ® . The '610 Patent is set to expire November 2 , 2027. About Vanda Pharmaceuticals Inc . Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc. , please visit www.vandapharma.com . About Fanapt ® For full U.S. Prescribing Information for Fanapt ® , including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com . Investor Contact: Jim Kelly Executive Vice President & Chief Financial Officer Vanda Pharmaceuticals Inc. (202) 734-3428 [email protected] View original content: http://www.prnewswire.com/news-releases/vanda-wins-appeal-case-on-fanapt-300629612.html SOURCE Vanda Pharmaceuticals Inc.
The release as fetched from its publisher. vandapharma.com ↗